TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:56
Akero Therapeutics Inc. ( AKRO ) https://www.akerotx.com
28.89USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AKRO
20.27%
SPY
32.66%
AKRO
36.34%
SPY
108.59%
AKRO
25.17%
SPY
302.52%
AKRO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2037.43
1357.18
0.34
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-8.59
7174.06
2.76
-11.84
0.00
-4.69
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-21110.56
-0.35
-25448.68
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.5776
-119.94
-64.34
0.07
Other Earnings and Cash Flow Stats:
Akero Therapeutics Inc. ( AKRO ) Net Income TTM ($MM) is -237.22
Akero Therapeutics Inc. ( AKRO ) Operating Income TTM ($MM) is -269.27
Akero Therapeutics Inc. ( AKRO ) Owners' Earnings Annual ($MM) is 0.00
Akero Therapeutics Inc. ( AKRO ) Current Price to Owners' Earnings ratio is 0.00
Akero Therapeutics Inc. ( AKRO ) EBITDA TTM ($MM) is -269.27
Akero Therapeutics Inc. ( AKRO ) EBITDA Margin is -25448.68%
Capital Allocation:
Akero Therapeutics Inc. ( AKRO ) has paid 0.00 dividends per share and bought back -13.829016 million shares in the past 12 months
Akero Therapeutics Inc. ( AKRO ) has increased its debt by 10.248 million USD in the last 12 months
Capital Structure:
Akero Therapeutics Inc. ( AKRO ) Interest-bearing Debt ($MM) as of last quarter is 36
Akero Therapeutics Inc. ( AKRO ) Annual Working Capital Investments ($MM) are 49
Akero Therapeutics Inc. ( AKRO ) Book Value ($MM) as of last quarter is 738
Akero Therapeutics Inc. ( AKRO ) Debt/Capital as of last quarter is 5%
Other Balance Sheet Stats:
Akero Therapeutics Inc. ( AKRO ) has 316 million in cash on hand as of last quarter
Akero Therapeutics Inc. ( AKRO ) has 43 million of liabilities due within 12 months, and long term debt 35 as of last quarter
Akero Therapeutics Inc. ( AKRO ) has 69 common shares outstanding as of last quarter
Akero Therapeutics Inc. ( AKRO ) has 0 million USD of preferred stock value
Academic Scores:
Akero Therapeutics Inc. ( AKRO ) Altman Z-Score is 14.00 as of last quarter
Akero Therapeutics Inc. ( AKRO ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Akero Therapeutics Inc. ( AKRO ) largest shareholder is owning shares at 0.00 ($MM) value
Rolph Timothy(an insider) Sold 3800 shares of Akero Therapeutics Inc. ( AKRO ) for the amount of $118172.40 on 2024-12-17
5.62% of Akero Therapeutics Inc. ( AKRO ) is held by insiders, and 105.36% is held by institutions
Akero Therapeutics Inc. ( AKRO ) went public on 2019-06-20
Other Akero Therapeutics Inc. ( AKRO ) financial metrics:
FCF:-211.65
Unlevered Free Cash Flow:0.00
EPS:-4.19
Operating Margin:-21110.56
Gross Profit Margin:-0.35
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-39.39
Beta:0.07
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Akero Therapeutics Inc. ( AKRO ) :
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.